The prevalence of asymptomatic and symptomatic COVID-19 in a cohort of quarantined subjects

•2714 individuals underwent mandatory quarantine.•136 individuals were SARS-CoV-2 positive on arrival, of whom the majority (92) were asymptomatic.•A further 52 individuals became SARS-CoV-2 positive over a 14-day period.•24 subjects found to be SARS-CoV-2 positive at day 14 remained asymptomatic un...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of infectious diseases Vol. 102; pp. 285 - 288
Main Authors Al-Qahtani, Manaf, AlAli, Salman, AbdulRahman, AbdulKarim, Salman Alsayyad, Adel, Otoom, Sameer, Atkin, Stephen L.
Format Journal Article
LanguageEnglish
Published Canada Elsevier Ltd 01.01.2021
The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases
Elsevier
Subjects
Online AccessGet full text

Cover

Loading…
Abstract •2714 individuals underwent mandatory quarantine.•136 individuals were SARS-CoV-2 positive on arrival, of whom the majority (92) were asymptomatic.•A further 52 individuals became SARS-CoV-2 positive over a 14-day period.•24 subjects found to be SARS-CoV-2 positive at day 14 remained asymptomatic until viral clearance.•Asymptomatic patients with COVID-19 were more prevalent than those exhibiting symptoms, and are an infection reservoir. The frequency of asymptomatic SARS-CoV-2 infection with viral spread is unclear. Asymptomatic SARS-CoV-2 infection development and progression was investigated in subjects undergoing mandatory quarantine on airport arrival. 2714 subjects were tested for SARS-CoV-2 and all were quarantined for 2 weeks. Viral retesting was undertaken on symptom development and routinely at 14 days if asymptomatic. Asymptomatic, positive patients underwent viral testing every 2 days to determine viral clearance. 188/2714 (6.9%) patients became SARS-CoV-2 positive. On arrival, 136/188 tested positive, with 44/188 (23.4%) symptomatic and 92/188 (48.9%) asymptomatic. All 92 patients remained asymptomatic and were retested every 2 days until viral clearance. 2526 quarantined subjects remained virus free at 14 days. Viral clearance did not differ between symptomatic and asymptomatic patients (12.6 ± 1.0 days and 12.1 ± 0.4 days, respectively). Of the 52/188 (27.7%) testing negative on arrival, 27/52 subsequently became positive and developed symptoms 2–13 days after arrival. 25/188 (13.3%) remained asymptomatic and tested positive at day 14, with viral testing undertaken every 2 days in these subjects; of these, 24 remained asymptomatic, with viral clearance at 9.4 ± 0.7 days — less than for those who were asymptomatic on arrival (p < 0.002). Asymptomatic patients with COVID-19 were more prevalent than those exhibiting symptoms, and are an infection reservoir.
AbstractList •2714 individuals underwent mandatory quarantine.•136 individuals were SARS-CoV-2 positive on arrival, of whom the majority (92) were asymptomatic.•A further 52 individuals became SARS-CoV-2 positive over a 14-day period.•24 subjects found to be SARS-CoV-2 positive at day 14 remained asymptomatic until viral clearance.•Asymptomatic patients with COVID-19 were more prevalent than those exhibiting symptoms, and are an infection reservoir. The frequency of asymptomatic SARS-CoV-2 infection with viral spread is unclear. Asymptomatic SARS-CoV-2 infection development and progression was investigated in subjects undergoing mandatory quarantine on airport arrival. 2714 subjects were tested for SARS-CoV-2 and all were quarantined for 2 weeks. Viral retesting was undertaken on symptom development and routinely at 14 days if asymptomatic. Asymptomatic, positive patients underwent viral testing every 2 days to determine viral clearance. 188/2714 (6.9%) patients became SARS-CoV-2 positive. On arrival, 136/188 tested positive, with 44/188 (23.4%) symptomatic and 92/188 (48.9%) asymptomatic. All 92 patients remained asymptomatic and were retested every 2 days until viral clearance. 2526 quarantined subjects remained virus free at 14 days. Viral clearance did not differ between symptomatic and asymptomatic patients (12.6 ± 1.0 days and 12.1 ± 0.4 days, respectively). Of the 52/188 (27.7%) testing negative on arrival, 27/52 subsequently became positive and developed symptoms 2–13 days after arrival. 25/188 (13.3%) remained asymptomatic and tested positive at day 14, with viral testing undertaken every 2 days in these subjects; of these, 24 remained asymptomatic, with viral clearance at 9.4 ± 0.7 days — less than for those who were asymptomatic on arrival (p < 0.002). Asymptomatic patients with COVID-19 were more prevalent than those exhibiting symptoms, and are an infection reservoir.
The frequency of asymptomatic SARS-CoV-2 infection with viral spread is unclear. Asymptomatic SARS-CoV-2 infection development and progression was investigated in subjects undergoing mandatory quarantine on airport arrival.BACKGROUNDThe frequency of asymptomatic SARS-CoV-2 infection with viral spread is unclear. Asymptomatic SARS-CoV-2 infection development and progression was investigated in subjects undergoing mandatory quarantine on airport arrival.2714 subjects were tested for SARS-CoV-2 and all were quarantined for 2 weeks. Viral retesting was undertaken on symptom development and routinely at 14 days if asymptomatic. Asymptomatic, positive patients underwent viral testing every 2 days to determine viral clearance.METHODS2714 subjects were tested for SARS-CoV-2 and all were quarantined for 2 weeks. Viral retesting was undertaken on symptom development and routinely at 14 days if asymptomatic. Asymptomatic, positive patients underwent viral testing every 2 days to determine viral clearance.188/2714 (6.9%) patients became SARS-CoV-2 positive. On arrival, 136/188 tested positive, with 44/188 (23.4%) symptomatic and 92/188 (48.9%) asymptomatic. All 92 patients remained asymptomatic and were retested every 2 days until viral clearance. 2526 quarantined subjects remained virus free at 14 days. Viral clearance did not differ between symptomatic and asymptomatic patients (12.6 ± 1.0 days and 12.1 ± 0.4 days, respectively). Of the 52/188 (27.7%) testing negative on arrival, 27/52 subsequently became positive and developed symptoms 2-13 days after arrival. 25/188 (13.3%) remained asymptomatic and tested positive at day 14, with viral testing undertaken every 2 days in these subjects; of these, 24 remained asymptomatic, with viral clearance at 9.4 ± 0.7 days - less than for those who were asymptomatic on arrival (p < 0.002).RESULTS188/2714 (6.9%) patients became SARS-CoV-2 positive. On arrival, 136/188 tested positive, with 44/188 (23.4%) symptomatic and 92/188 (48.9%) asymptomatic. All 92 patients remained asymptomatic and were retested every 2 days until viral clearance. 2526 quarantined subjects remained virus free at 14 days. Viral clearance did not differ between symptomatic and asymptomatic patients (12.6 ± 1.0 days and 12.1 ± 0.4 days, respectively). Of the 52/188 (27.7%) testing negative on arrival, 27/52 subsequently became positive and developed symptoms 2-13 days after arrival. 25/188 (13.3%) remained asymptomatic and tested positive at day 14, with viral testing undertaken every 2 days in these subjects; of these, 24 remained asymptomatic, with viral clearance at 9.4 ± 0.7 days - less than for those who were asymptomatic on arrival (p < 0.002).Asymptomatic patients with COVID-19 were more prevalent than those exhibiting symptoms, and are an infection reservoir.CONCLUSIONAsymptomatic patients with COVID-19 were more prevalent than those exhibiting symptoms, and are an infection reservoir.
Background: The frequency of asymptomatic SARS-CoV-2 infection with viral spread is unclear. Asymptomatic SARS-CoV-2 infection development and progression was investigated in subjects undergoing mandatory quarantine on airport arrival. Methods: 2714 subjects were tested for SARS-CoV-2 and all were quarantined for 2 weeks. Viral retesting was undertaken on symptom development and routinely at 14 days if asymptomatic. Asymptomatic, positive patients underwent viral testing every 2 days to determine viral clearance. Results: 188/2714 (6.9%) patients became SARS-CoV-2 positive. On arrival, 136/188 tested positive, with 44/188 (23.4%) symptomatic and 92/188 (48.9%) asymptomatic. All 92 patients remained asymptomatic and were retested every 2 days until viral clearance. 2526 quarantined subjects remained virus free at 14 days. Viral clearance did not differ between symptomatic and asymptomatic patients (12.6 ± 1.0 days and 12.1 ± 0.4 days, respectively). Of the 52/188 (27.7%) testing negative on arrival, 27/52 subsequently became positive and developed symptoms 2–13 days after arrival. 25/188 (13.3%) remained asymptomatic and tested positive at day 14, with viral testing undertaken every 2 days in these subjects; of these, 24 remained asymptomatic, with viral clearance at 9.4 ± 0.7 days — less than for those who were asymptomatic on arrival (p < 0.002). Conclusion: Asymptomatic patients with COVID-19 were more prevalent than those exhibiting symptoms, and are an infection reservoir.
The frequency of asymptomatic SARS-CoV-2 infection with viral spread is unclear. Asymptomatic SARS-CoV-2 infection development and progression was investigated in subjects undergoing mandatory quarantine on airport arrival. 2714 subjects were tested for SARS-CoV-2 and all were quarantined for 2 weeks. Viral retesting was undertaken on symptom development and routinely at 14 days if asymptomatic. Asymptomatic, positive patients underwent viral testing every 2 days to determine viral clearance. 188/2714 (6.9%) patients became SARS-CoV-2 positive. On arrival, 136/188 tested positive, with 44/188 (23.4%) symptomatic and 92/188 (48.9%) asymptomatic. All 92 patients remained asymptomatic and were retested every 2 days until viral clearance. 2526 quarantined subjects remained virus free at 14 days. Viral clearance did not differ between symptomatic and asymptomatic patients (12.6 ± 1.0 days and 12.1 ± 0.4 days, respectively). Of the 52/188 (27.7%) testing negative on arrival, 27/52 subsequently became positive and developed symptoms 2-13 days after arrival. 25/188 (13.3%) remained asymptomatic and tested positive at day 14, with viral testing undertaken every 2 days in these subjects; of these, 24 remained asymptomatic, with viral clearance at 9.4 ± 0.7 days - less than for those who were asymptomatic on arrival (p < 0.002). Asymptomatic patients with COVID-19 were more prevalent than those exhibiting symptoms, and are an infection reservoir.
Author Atkin, Stephen L.
AbdulRahman, AbdulKarim
Otoom, Sameer
Salman Alsayyad, Adel
Al-Qahtani, Manaf
AlAli, Salman
Author_xml – sequence: 1
  givenname: Manaf
  orcidid: 0000-0002-1523-0429
  surname: Al-Qahtani
  fullname: Al-Qahtani, Manaf
  email: mqahtani@rcsi-mub.com
  organization: Bahrain Defense Force Hospital, Bahrain
– sequence: 2
  givenname: Salman
  surname: AlAli
  fullname: AlAli, Salman
  email: salmanyalali@gmail.com
  organization: Bahrain Defense Force Hospital, Bahrain
– sequence: 3
  givenname: AbdulKarim
  orcidid: 0000-0002-7331-388X
  surname: AbdulRahman
  fullname: AbdulRahman, AbdulKarim
  email: abdulkarim.md@live.com
  organization: Mohammed bin Khalifa Cardiac Centre, Bahrain
– sequence: 4
  givenname: Adel
  surname: Salman Alsayyad
  fullname: Salman Alsayyad, Adel
  email: ASayyad@health.gov.bh
  organization: Ministry of Health, Bahrain
– sequence: 5
  givenname: Sameer
  surname: Otoom
  fullname: Otoom, Sameer
  email: sotoom@rcsi.com
  organization: Royal College of Surgeons, Bahrain
– sequence: 6
  givenname: Stephen L.
  orcidid: 0000-0002-5887-7257
  surname: Atkin
  fullname: Atkin, Stephen L.
  email: satkin@rcsi.com
  organization: Royal College of Surgeons, Bahrain
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33157290$$D View this record in MEDLINE/PubMed
BookMark eNqFUstu1DAUjVARfcAPsEBZsslgO4kfCCGhgcJIlbopbFhYjn3TccjYUzsZaf4eu1Oqtouy8eP6nHOvfM5pceS8g6J4i9ECI0w_DAs7WLMgiOTCAgn8ojjBnPGqbjE-SmeCcCUYJsfFaYwDQqihlL8qjusat4wIdFL8vlpDuQ2wUyM4DaXvSxX3m-3kN2qyulTOlA_vy8tfq68VFqV1pSq1X_swZdLNrIJyk3WQ8HM3gJ7i6-Jlr8YIb-72s-Ln-ber5Y_q4vL7avnlotJpiKnqe94pIIYwSqEWuOc1apoWsZbptPCeYqMYgOEtbkTdkg61tGs7hBuksRb1WbE66BqvBrkNdqPCXnpl5W3Bh2upQhp-BNk2RlGsGU4NG0yF0koQyqBHPaeNyVqfD1rbuduA0eCmoMZHoo9fnF3La7-TjCJGKEkC7-8Egr-ZIU5yY6OGcVQO_BwlaVrOSM1Fhr572Ou-yT93EoAcADr4GAP09xCMZI6AHGSOgMwRyLUUgUTiT0jaTsk7n-e14_PUTwcqJLd2FoKM2uZYGBuSoek77fP0j0_oerTOajX-gf3_yH8BAKPfRA
CitedBy_id crossref_primary_10_1016_j_jobcr_2021_10_001
crossref_primary_10_1016_j_wneu_2021_03_055
crossref_primary_10_1016_j_ijid_2021_02_100
crossref_primary_10_1016_j_tmaid_2021_102127
crossref_primary_10_1038_s41598_023_42754_2
crossref_primary_10_1073_pnas_2109229118
crossref_primary_10_3389_fpubh_2023_1216113
crossref_primary_10_4103_NJM_NJM_113_21
crossref_primary_10_1080_17477778_2023_2189027
crossref_primary_10_1080_23744235_2022_2131899
crossref_primary_10_1016_j_ijbiomac_2021_11_016
crossref_primary_10_1371_journal_pmed_1003987
crossref_primary_10_2139_ssrn_3925475
crossref_primary_10_1016_S2666_5247_22_00259_2
crossref_primary_10_3390_ijerph20054651
crossref_primary_10_1098_rsif_2022_0498
crossref_primary_10_3389_fmed_2023_1132476
crossref_primary_10_1371_journal_pone_0271259
crossref_primary_10_1007_s12070_022_03112_2
crossref_primary_10_1007_s40314_021_01592_6
crossref_primary_10_1093_jtm_taab037
crossref_primary_10_1001_jamanetworkopen_2021_37257
crossref_primary_10_1016_j_ijregi_2022_02_007
crossref_primary_10_2147_IJGM_S374090
crossref_primary_10_1016_j_psychres_2023_115631
crossref_primary_10_1016_j_jinf_2024_106238
crossref_primary_10_1016_j_chaos_2024_114695
crossref_primary_10_2147_IJGM_S396357
crossref_primary_10_2196_27254
crossref_primary_10_24018_ejmed_2022_4_1_1213
crossref_primary_10_3389_fpubh_2021_644199
crossref_primary_10_34172_ehsj_2023_05
crossref_primary_10_1016_j_curtheres_2024_100733
crossref_primary_10_4178_epih_e2022085
crossref_primary_10_1038_s41598_022_06159_x
crossref_primary_10_1016_j_puhip_2021_100145
crossref_primary_10_7759_cureus_24194
Cites_doi 10.2807/1560-7917.ES.2020.25.10.2000180
10.7326/M20-3012
10.2807/1560-7917.ES.2020.25.5.2000062
10.1111/anae.15072
10.7326/M20-0504
10.1016/S2214-109X(20)30074-7
10.1056/NEJMc2001737
10.2807/1560-7917.ES.2020.25.3.2000045
10.1056/NEJMoa2008457
10.1016/j.jaut.2020.102433
10.1016/j.ijid.2020.03.020
ContentType Journal Article
Copyright 2020 The Author(s)
Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.
2020 The Author(s) 2020
Copyright_xml – notice: 2020 The Author(s)
– notice: Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.
– notice: 2020 The Author(s) 2020
DBID 6I.
AAFTH
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOA
DOI 10.1016/j.ijid.2020.10.091
DatabaseName ScienceDirect Open Access Titles
Elsevier:ScienceDirect:Open Access
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic


MEDLINE
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Public Health
EISSN 1878-3511
EndPage 288
ExternalDocumentID oai_doaj_org_article_54da61c71ae24169aca9267ef0f864d9
PMC7607262
33157290
10_1016_j_ijid_2020_10_091
S1201971220322943
Genre Journal Article
GeographicLocations Bahrain
GeographicLocations_xml – name: Bahrain
GroupedDBID ---
--K
.1-
.FO
.~1
0R~
1B1
1P~
1~.
1~5
29J
3O-
4.4
457
4G.
53G
5GY
5VS
7-5
71M
7X7
88E
8C1
8FI
8FJ
8FQ
8R4
8R5
AAEDW
AAFWJ
AAIKJ
AALRI
AAQFI
AAQXK
AARKO
AAXUO
AAYWO
ABBQC
ABFRF
ABMAC
ABUWG
ABWVN
ACGFO
ACRPL
ACVFH
ADBBV
ADCNI
ADEZE
ADMUD
ADNMO
ADVLN
AEFWE
AEKER
AENEX
AEUPX
AEVXI
AEXQZ
AFJKZ
AFKRA
AFPKN
AFPUW
AFRHN
AFTJW
AGEKW
AGHFR
AGQPQ
AGYEJ
AHMBA
AIGII
AITUG
AJRQY
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
APXCP
ASPBG
AVWKF
AZFZN
BAWUL
BCNDV
BENPR
BPHCQ
BR6
BVXVI
CCPQU
CS3
DIK
DU5
DWQXO
E3Z
EBS
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FNPLU
FYUFA
G-Q
GBLVA
GROUPED_DOAJ
GX1
HMCUK
HVGLF
HZ~
IHE
IXB
J1W
KQ8
M1P
M3C
M3G
M41
MO0
N9A
O-L
O9-
OD-
OK1
OO.
OZT
P-8
P-9
P2P
PC.
PHGZM
PHGZT
PJZUB
PPXIY
PQQKQ
PROAC
PSQYO
PUEGO
Q2X
Q38
QTD
R2-
ROL
RPZ
RWL
RXW
SDF
SDG
SEL
SES
SEW
SSZ
TAE
UKHRP
UNMZH
Z5R
0SF
3V.
6I.
AACTN
AAFTH
ABVKL
AFCTW
NCXOZ
RIG
AAYXX
ALIPV
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ID FETCH-LOGICAL-c572t-ff8bae2d2766e391f8304450757c0758f61da7eed85149352b056b5b0140c1c93
IEDL.DBID IXB
ISSN 1201-9712
1878-3511
IngestDate Wed Aug 27 01:31:34 EDT 2025
Thu Aug 21 18:07:11 EDT 2025
Sun Aug 24 03:47:45 EDT 2025
Thu Apr 03 07:05:17 EDT 2025
Tue Jul 01 04:29:56 EDT 2025
Thu Apr 24 22:52:18 EDT 2025
Fri Feb 23 02:44:41 EST 2024
Tue Aug 26 16:33:02 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords COVID-19
Screening
SARS-CoV-2
Symptoms
Language English
License This is an open access article under the CC BY-NC-ND license.
Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c572t-ff8bae2d2766e391f8304450757c0758f61da7eed85149352b056b5b0140c1c93
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Joint senior authors.
ORCID 0000-0002-7331-388X
0000-0002-5887-7257
0000-0002-1523-0429
OpenAccessLink https://www.sciencedirect.com/science/article/pii/S1201971220322943
PMID 33157290
PQID 2458723892
PQPubID 23479
PageCount 4
ParticipantIDs doaj_primary_oai_doaj_org_article_54da61c71ae24169aca9267ef0f864d9
pubmedcentral_primary_oai_pubmedcentral_nih_gov_7607262
proquest_miscellaneous_2458723892
pubmed_primary_33157290
crossref_primary_10_1016_j_ijid_2020_10_091
crossref_citationtrail_10_1016_j_ijid_2020_10_091
elsevier_sciencedirect_doi_10_1016_j_ijid_2020_10_091
elsevier_clinicalkey_doi_10_1016_j_ijid_2020_10_091
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-01-01
PublicationDateYYYYMMDD 2021-01-01
PublicationDate_xml – month: 01
  year: 2021
  text: 2021-01-01
  day: 01
PublicationDecade 2020
PublicationPlace Canada
PublicationPlace_xml – name: Canada
PublicationTitle International journal of infectious diseases
PublicationTitleAlternate Int J Infect Dis
PublicationYear 2021
Publisher Elsevier Ltd
The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases
Elsevier
Publisher_xml – name: Elsevier Ltd
– name: The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases
– name: Elsevier
References Corman, Landt, Kaiser, Molenkamp, Meijer, Chu (bib0025) 2020; 25
Fogarty, Townsend, Ni Cheallaigh, Bergin, Martin-Loeches, Browne (bib0030) 2020
Zou, Ruan, Huang, Liang, Huang, Hong (bib0065) 2020; 382
Mizumoto, Kagaya, Zarebski, Chowell (bib0045) 2020; 25
Nishiura, Kobayashi, Miyama, Suzuki, Jung, Hayashi (bib0050) 2020; 94
Carenzo, Costantini, Greco, Barra, Rendiniello, Mainetti (bib0015) 2020
CDC (bib0020) 2020
Rothan, Byrareddy (bib0060) 2020; 109
Oran, Topol (bib0055) 2020
Backer, Klinkenberg, Wallinga (bib0010) 2020; 25
Arons, Hatfield, Reddy, Kimball, James, Jacobs (bib0005) 2020; 382
Lauer, Grantz, Bi, Jones, Zheng, Meredith (bib0040) 2020; 172
Hellewell, Abbott, Gimma, Bosse, Jarvis, Russell (bib0035) 2020; 8
Rothan (10.1016/j.ijid.2020.10.091_bib0060) 2020; 109
Arons (10.1016/j.ijid.2020.10.091_bib0005) 2020; 382
CDC (10.1016/j.ijid.2020.10.091_bib0020) 2020
Mizumoto (10.1016/j.ijid.2020.10.091_bib0045) 2020; 25
Oran (10.1016/j.ijid.2020.10.091_bib0055) 2020
Backer (10.1016/j.ijid.2020.10.091_bib0010) 2020; 25
Fogarty (10.1016/j.ijid.2020.10.091_bib0030) 2020
Carenzo (10.1016/j.ijid.2020.10.091_bib0015) 2020
Lauer (10.1016/j.ijid.2020.10.091_bib0040) 2020; 172
Zou (10.1016/j.ijid.2020.10.091_bib0065) 2020; 382
Hellewell (10.1016/j.ijid.2020.10.091_bib0035) 2020; 8
Corman (10.1016/j.ijid.2020.10.091_bib0025) 2020; 25
Nishiura (10.1016/j.ijid.2020.10.091_bib0050) 2020; 94
References_xml – year: 2020
  ident: bib0055
  article-title: Prevalence of asymptomatic SARS-CoV-2 infection: a narrative review
  publication-title: Ann Intern Med
– volume: 94
  start-page: 154
  year: 2020
  end-page: 155
  ident: bib0050
  article-title: Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19)
  publication-title: Int J Infect Dis
– year: 2020
  ident: bib0020
  article-title: Pandemic Planning Scenarios
– year: 2020
  ident: bib0030
  article-title: COVID-19 coagulopathy in caucasian patients
  publication-title: Br Haematol
– year: 2020
  ident: bib0015
  article-title: Hospital surge capacity in a tertiary emergency referral centre during the COVID-19 outbreak in Italy
  publication-title: Anaesthesia
– volume: 25
  year: 2020
  ident: bib0025
  article-title: Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR
  publication-title: Euro Surveill
– volume: 25
  year: 2020
  ident: bib0010
  article-title: Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20–28 January 2020
  publication-title: Euro Surveill
– volume: 25
  year: 2020
  ident: bib0045
  article-title: Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020
  publication-title: Euro Surveill
– volume: 382
  start-page: 2081
  year: 2020
  end-page: 2090
  ident: bib0005
  article-title: Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility
  publication-title: N Engl J Med
– volume: 109
  year: 2020
  ident: bib0060
  article-title: The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak
  publication-title: J Autoimmunity
– volume: 172
  start-page: 577
  year: 2020
  end-page: 582
  ident: bib0040
  article-title: The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application
  publication-title: Ann Intern Med
– volume: 382
  start-page: 1177
  year: 2020
  end-page: 1179
  ident: bib0065
  article-title: SARS-CoV-2 viral load in upper respiratory specimens of infected patients
  publication-title: N Engl J Med
– volume: 8
  start-page: e488
  year: 2020
  end-page: 96
  ident: bib0035
  article-title: Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts
  publication-title: Lancet Global Health
– volume: 25
  issue: 10
  year: 2020
  ident: 10.1016/j.ijid.2020.10.091_bib0045
  article-title: Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020
  publication-title: Euro Surveill
  doi: 10.2807/1560-7917.ES.2020.25.10.2000180
– year: 2020
  ident: 10.1016/j.ijid.2020.10.091_bib0055
  article-title: Prevalence of asymptomatic SARS-CoV-2 infection: a narrative review
  publication-title: Ann Intern Med
  doi: 10.7326/M20-3012
– volume: 25
  issue: 5
  year: 2020
  ident: 10.1016/j.ijid.2020.10.091_bib0010
  article-title: Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20–28 January 2020
  publication-title: Euro Surveill
  doi: 10.2807/1560-7917.ES.2020.25.5.2000062
– year: 2020
  ident: 10.1016/j.ijid.2020.10.091_bib0015
  article-title: Hospital surge capacity in a tertiary emergency referral centre during the COVID-19 outbreak in Italy
  publication-title: Anaesthesia
  doi: 10.1111/anae.15072
– volume: 172
  start-page: 577
  issue: 9
  year: 2020
  ident: 10.1016/j.ijid.2020.10.091_bib0040
  article-title: The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application
  publication-title: Ann Intern Med
  doi: 10.7326/M20-0504
– volume: 8
  start-page: e488
  issue: 4
  year: 2020
  ident: 10.1016/j.ijid.2020.10.091_bib0035
  article-title: Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts
  publication-title: Lancet Global Health
  doi: 10.1016/S2214-109X(20)30074-7
– year: 2020
  ident: 10.1016/j.ijid.2020.10.091_bib0030
  article-title: COVID-19 coagulopathy in caucasian patients
  publication-title: Br Haematol
– volume: 382
  start-page: 1177
  issue: 12
  year: 2020
  ident: 10.1016/j.ijid.2020.10.091_bib0065
  article-title: SARS-CoV-2 viral load in upper respiratory specimens of infected patients
  publication-title: N Engl J Med
  doi: 10.1056/NEJMc2001737
– year: 2020
  ident: 10.1016/j.ijid.2020.10.091_bib0020
– volume: 25
  issue: 3
  year: 2020
  ident: 10.1016/j.ijid.2020.10.091_bib0025
  article-title: Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR
  publication-title: Euro Surveill
  doi: 10.2807/1560-7917.ES.2020.25.3.2000045
– volume: 382
  start-page: 2081
  issue: 22
  year: 2020
  ident: 10.1016/j.ijid.2020.10.091_bib0005
  article-title: Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2008457
– volume: 109
  year: 2020
  ident: 10.1016/j.ijid.2020.10.091_bib0060
  article-title: The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak
  publication-title: J Autoimmunity
  doi: 10.1016/j.jaut.2020.102433
– volume: 94
  start-page: 154
  year: 2020
  ident: 10.1016/j.ijid.2020.10.091_bib0050
  article-title: Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19)
  publication-title: Int J Infect Dis
  doi: 10.1016/j.ijid.2020.03.020
SSID ssj0004668
Score 2.462312
Snippet •2714 individuals underwent mandatory quarantine.•136 individuals were SARS-CoV-2 positive on arrival, of whom the majority (92) were asymptomatic.•A further...
The frequency of asymptomatic SARS-CoV-2 infection with viral spread is unclear. Asymptomatic SARS-CoV-2 infection development and progression was investigated...
Background: The frequency of asymptomatic SARS-CoV-2 infection with viral spread is unclear. Asymptomatic SARS-CoV-2 infection development and progression was...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
elsevier
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 285
SubjectTerms Adult
Aged
Aged, 80 and over
Asymptomatic Infections - epidemiology
Bahrain - epidemiology
Cohort Studies
COVID-19
COVID-19 - diagnosis
COVID-19 - epidemiology
COVID-19 - prevention & control
COVID-19 Testing
Female
Humans
Male
Middle Aged
Prevalence
Quarantine
SARS-CoV-2
Screening
Symptoms
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Ni9QwFA-yBxFEdP2qX0TwJtXmuznq6rIKqxdXFjyUtEmwi3bGmc7B_973mrZMFXYvXgaaSWZI3i99v6bv_R4hL3xUSujAc8Ebn0sRWG4jl7kEbgoY0ppLzB0-_aRPzuTHc3W-V-oLY8KSPHBauNdKeqdZY5gL4Gy0dY2zXJsQi1hq6YfUPfB508PUnBGZkuDAveXWMD6my6TIrvaiRY1Qjg2vCssWLmlQ7l94pn-Z598BlHse6fg2uTVSSfomTeEOuRa6Q3L9dHxZfkhupiM5mjKN7pJvAAm63qC-N25nuorUbX__XPerQbaVus7T_eujz18_vMuZpW1HHcVKupseB_0CVDksMBGg_67Gg5ztPXJ2_P7L0Uk-1lbIG2V4n8dY1rCinhutg7AslqKQEsihMg18lFEz7ww4UGBk0gJLq4Ep1arGB7KGNVbcJwfdqgsPCQ1ReXD0hXFOyqCKWnhWayec81oBYckIm5a3akbhcax_8aOaIswuKjRJhSbBNjBJRl7OY9ZJduPS3m_RanNPlMweGgBI1Qik6iogZURMNq-mrFS4j8IPtZf-tZpHjZwlcZErxz2fYFXBhsa3NK4Lq9224lKVWAnO8ow8SDCbJyYEA-vZIiNmAcDFzJffdO33QTTc6MJwzR_9j6V6TG5wDO0ZTqKekIN-swtPgZv19bNhG_4BKoEziQ
  priority: 102
  providerName: Directory of Open Access Journals
Title The prevalence of asymptomatic and symptomatic COVID-19 in a cohort of quarantined subjects
URI https://www.clinicalkey.com/#!/content/1-s2.0-S1201971220322943
https://dx.doi.org/10.1016/j.ijid.2020.10.091
https://www.ncbi.nlm.nih.gov/pubmed/33157290
https://www.proquest.com/docview/2458723892
https://pubmed.ncbi.nlm.nih.gov/PMC7607262
https://doaj.org/article/54da61c71ae24169aca9267ef0f864d9
Volume 102
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Li9RAEG7WPYggi66v-Bha8CbZSb_TR3d0WZVVRFcGPIROuqNZ3Mw4kzl48bdblccwUVjBSyCd6iSdqnR96VR9RcgzXyoldOCx4IWPpQgstiWXsQRsCjakNZeYO3z2Tp-eyzdzNd8jsyEXBsMq-7m_m9Pb2bpvmfZPc7qsqulHBr7LGsaxBji3Ehk_hUzbJL758U5uZJcOB8IxSveJM12MV3VRIVsox4ajxLKRc2o5_Ec-6m8M-mco5Y5vOrlFDnpQSV90932b7IX6kFw_63-bH5Kb3eIc7XKO7pAvYBx0uUKmbxwwXZTUrX9eLptFS-BKXe3p7v7s_efXL2NmaVVTR7Gm7qrBTj_AvhyWmgggv8lxSWd9l5yfvPo0O437KgtxoQxv4rJMcxe450brICwrU5FICTBRmQI2aamZdwZcKWAzaQGv5YCZcpXjp1nBCivukf16UYcHhIZSeXD5iXFOyqCSXHiWayec81oBdIkIGx5vVvQU5FgJ43s2xJpdZKiSDFWCbaCSiDzf9ll2BBxXSh-j1raSSJ7dNixWX7PeejIlvdOsMAyGDXjUusJZrk0okzLV0tuIiEHn2ZCfCjMqnKi68tJq22tkwf_s93Qwqwxebfxf4-qw2KwzLlWKNeEsj8j9zsy2AxOCgfZsEhEzMsDRyMdH6upbSx9udGK45g__834fkRsc43raZajHZL9ZbcITAGZNPiHXjn6xSbusMWnfQti-_ZD-BsZlNpg
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELaWRYKVEILlFZ5G4oZC43d9ZAurFrbLgV1UiUPkJA5ktSSlTQ_8e2byqBqQFolLpDjjxPaMPV_seRDyKsuVEtrzUPA0C6XwLLQ5l6EEbAoypDWX6Ds8P9XTc_lhoRZ7ZNL7wqBZZbf2t2t6s1p3JaNuNEfLohh9ZqC7rGEcc4BzK8U1ch3QgMH8DbPF0Y5zZOsPB9QhkneeM62RV3FRYLhQjgVvIssG2qkJ4j9QUn-D0D9tKXeU0_EdcrtDlfRt2_C7ZM-Xh-TGvDs3PyS32t052jod3SNfQTrocoWhvrHHtMqpW__6sayrJoIrdWVGd-8nn77M3oXM0qKkjmJS3VWNlX6CgDnMNeGBfpPgns76Pjk_fn82mYZdmoUwVYbXYZ6PE-d5xo3WXliWj0UkJeBEZVK4jHPNMmdAlwI4kxYAWwKgKVEJ_pulLLXiAdkvq9I_ItTnKgOdHxnnpPQqSkTGEu2Ec5lWgF0CwvrhjdMuBjmmwriMe2OzixhZEiNLsAxYEpDX2zrLNgLHldRHyLUtJUbPbgqq1be4E59YycxplhoG3QZAal3qLNfG51E-1jKzARE9z-PeQRWWVHhRceWn1bbWQIT_We9lL1YxzG08sHGlrzbrmEs1xqRwlgfkYStm244JwYB7NgqIGQjgoOfDJ2XxvYkfbnRkuOaP_7O9L8jN6dn8JD6ZnX58Qg44Gvk0e1JPyX692vhngNLq5HkzC38DeBo2zw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+prevalence+of+asymptomatic+and+symptomatic+COVID-19+in+a+cohort+of+quarantined+subjects&rft.jtitle=International+journal+of+infectious+diseases&rft.au=Al-Qahtani%2C+Manaf&rft.au=AlAli%2C+Salman&rft.au=AbdulRahman%2C+AbdulKarim&rft.au=Salman+Alsayyad%2C+Adel&rft.date=2021-01-01&rft.pub=Elsevier+Ltd&rft.issn=1201-9712&rft.eissn=1878-3511&rft.volume=102&rft.spage=285&rft.epage=288&rft_id=info:doi/10.1016%2Fj.ijid.2020.10.091&rft.externalDocID=S1201971220322943
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1201-9712&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1201-9712&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1201-9712&client=summon